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There is a paucity of data on the effects of overt nephropathy
and moderate renal impairment on endothelial function in
diabetic patients. A total of 26 type II diabetic (DM) patients
with nephropathy (DMNþ ) (mean7s.d. age: 63.776.3 years),
32 diabetic patients without nephropathy (DMN) (59.4710.1
years), and 52 non-diabetic subjects (54.978.2 years) were
recruited. High-resolution ultrasound scan was used to
measure carotid intima media thickness (IMT) and
flow-mediated dilation (FMD) of the brachial artery.
Endothelium-independent dilation was determined by
maximal vascular dilation after sublingual nitroglycerine
(glyceryl trinitrate (GTN)-induced dilation). The mean carotid
IMT increased progressively from non-DM to DMN to DMNþ
groups (0.7470.23 vs 0.8070.25 vs 1.0370.38 mm; P¼ 0.001
for trend) whereas FMD- (4.372.5 vs 3.971.7 vs 1.972.0%,
Po0.001 for trend) and GTN-induced dilation (14.774.0 vs
14.573.9 vs 10.373.2%; Po0.001 for trend) declined in an
opposite manner. On multivariate analysis, age (b¼ 0.257,
P¼ 0.009), glomerular filtration rate (b¼0.364, Po0.001),
and smoking (b¼ 0.25, P¼ 0.013) were independently
associated with carotid IMT (F¼ 15.76, R2¼ 0.340, Po0.001).
After adjustment for baseline brachial arterial diameter, history
of smoking (b¼0.039, Po0.001), fasting plasma glucose
(b¼0.033, P¼ 0.002), and total cholesterol (b¼0.023,
P¼ 0.024) were independently associated with vessel diameter
after FMD (F¼ 2446.5, R2¼ 0.992, Po0.001); whereas age
(b¼0.069, P¼ 0.001) and urinary albumin excretion
(b¼0.048, P¼ 0.018) were independently associated with
vessel diameter after GTN (F¼ 851.6, R2¼ 0.967, Po0.001).
Type II diabetic patients with overt nephropathy and moderate
renal impairment had both structural and functional vascular
abnormalities beyond the endothelium.
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The development of micro- and macroalbuminuria signifi-
cantly escalates the risk of cardiovascular morbidity and
premature mortality in type II diabetic (DM) patients1–4
including Chinese.5,6 There is growing evidence supporting
that dysfunction of the vascular endothelium accounts for
the propensity for atherosclerosis in this high-risk patient
population. Flow-mediated dilation (FMD) as assessed by
high-resolution ultrasound has been firmly established as a
surrogate marker of generalized atherosclerosis.7,8 Numerous
studies have shown close association between impaired
FMD and traditional cardiovascular risk factors9 including
type I and type II diabetes.10,11 Furthermore, FMD is predic-
tive of coronary events12 and the severity of FMD impair-
ment correlates with that of coronary heart disease.13
More recently, chronic kidney disease has been found to be
an independent predictor for cardiovascular events14,15
especially in diabetic patients.16 Whereas several studies
have shown associations between microalbuminuria
and endothelial dysfunction in both type I and type II
diabetes,7,17,18 there are limited data on the effects of overt
diabetic nephropathy and renal insufficiency on vascular
function in type II diabetes.
In this case–control cohort analysis, we examined the
effects of moderate renal insufficiency and albuminuria
on endothelium-dependent dilation and endothelium-
independent dilation in type II diabetic patients and non-
diabetic control subjects. We also examined the structural
abnormalities of conduit vessels as reflected by common
carotid intima-media thickness (IMT), another established
marker of cardiovascular diseases.19–21
RESULTS
Among the three groups, patients in the DMNþ group
were older, more likely to be smokers, had higher waist
circumference, body mass index, systolic blood pressure,
worse glucose, and lipid control as well as higher albuminuria
and lower glomerular filtration rate (GFR) compared to
the DMN and non-DM group (Table 1). The mean carotid
IMT increased progressively from non-DM to DMN to
DMNþ groups (0.7470.23 vs 0.870.25 vs 1.0370.38 mm;
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P¼ 0.001 for trend). FMD (4.372.5 vs 3.971.7 vs 1.97
2.0%, Po0.001 for trend) and endothelium-independent
dilation (14.774.0 vs 14.573.9 vs 10.373.2%; Po0.001 for
trend) declined in an opposite manner (Figure 1). The
baseline brachial artery diameter also increased progressively
from non-DM to DMN to DMNþ groups (4.0670.74 vs
4.1570.62 vs 4.8570.68 mm, Po0.001 for trend). Peak
systolic velocity did not differ among the three groups both at
baseline (72.475.0 vs 69.474.8 vs 72.173.9 cm/s P¼ 0.406
for trend) and post-deflation of cuff (123.9715.7 vs
121.9712.6 vs 116.0712.4 cm/s. P¼ 0.073 for trend). Vessel
diameter after FMD showed progressive decrease from
non-DM to DMN to DMNþ groups (4.4470.18 vs
4.4370.18 vs 4.3570.19 mm Po0.001 for trend) after
adjustment for baseline vessel diameter. Vessel diameter
after glyceryl trinitrate (GTN) showed progressive decrease
from non-DM to DMN to DMNþ groups (4.8670.31 vs
4.8870.31 vs 4.73 70.16 mm; Po0.001 for trend) after
adjustment for baseline vessel diameter.
Multiple stepwise linear regression analysis was performed
using age, sex, smoking (current and ex-smoker), blood
pressure, body mass index, waist circumference, fasting
plasma glucose, glycated hemoglobin, total cholesterol
(TC), high-density lipoprotein cholesterol, low-density
lipoprotein cholesterol, triglyceride, GFR, and urinary
albumin excretion (UAE) as dependent variables to identify
independent predictors for IMT in the entire cohort of 110
control and diabetic subjects. The same set of independent
variables together with baseline brachial artery diameter was
used to identify independent predictors of vessel diameter
after FMD and GTN.
Age (b¼ 0.257, P¼ 0.009), GFR (b¼0.364, Po0.001),
and smoking (b¼ 0.25, P¼ 0.013) were independently
associated with carotid IMT (F¼ 15.76, R2¼ 0.340,
Po0.001). Baseline brachial artery diameter (b¼ 1.007,
Po0.001), smoking (b¼0.039, Po0.001), fasting plasma
glucose (b¼0.033, P¼ 0.002), TC (b¼0.023, P¼ 0.024)
were independently associated with vessel diameter after
FMD (F¼ 2446.5, R2¼ 0.992, Po0.001). Baseline brachial
artery diameter (b¼ 1.013, Po0.001), age (b¼0.069,
P¼ 0.001), and UAE (b¼0.048, P¼ 0.018) were indepen-
dently associated with vessel diameter after GTN (F¼ 851.6,
R2¼ 0.967, Po0.001). Association between UAE and
GTN-induced dilation is shown in Figure 2.
DISCUSSION
The major findings of this study are that in type II diabetic
patients, the presence of overt nephropathy and mode-
rate renal insufficiency was significantly associated with
reduced endothelium-dependent dilation and endothelium-
independent dilation as reflected by reduced response of
vascular smooth muscle cells (VSMC) to nitric oxide (NO)
Table 1 | Comparison of baseline clinical and biochemical characteristics of Chinese type II diabetic patients with (DMN+) and
without overt nephropathy and renal insufficiency (DMN) as well as control subjects
Parameters DMN+ DMN Control subjects P-value (ANOVA)
Number 26 32 52 —
Age (years) 63.7 (6.3) 59.4 (10.1) 54.9 (8.2) o0.001
Duration of diabetes (years) 16.7 6.7 NA o0.001
Sex (M:F) 9:17 20:12 32:20 0.050
Smoker (ex and current) 57.7% 18.8% 19.2% 0.001
Body mass index (kg/m2) 25.3 (2.6) 25.1 (3.4) 23.5 (2.5) 0.012
Waist circumference (cm) 93.6 (9.3) 86.0 (8.4) 82.8 (9.7) o0.001
Systolic BP (mm Hg) 127 (19) 138 (20) 126 (20) 0.043
Diastolic BP (mm Hg) 85 (9) 79 (14) 83 (10) 0.174
FPG (mmol/l) 7.2 (2.0) 6.4 (1.7) 5.1 (0.4) o0.001
HbA1c (%) 7.3 (1.5) 6.8 (1.4) 5.5 (1.2) o0.001
TC (mmol/l) 5.0 (1.3) 5.0 (0.8) 5.5 (0.9) 0.046
TG (mmol/l) 2.12 (1.63) 1.34 (0.63) 1.40 (0.68) 0.002
HDL-C (mmol/l) 1.14 (0.26) 1.39 (0.30) 1.48 (0.34) 0.001
LDL-C (mmol/l) 3.0 (0.9) 2.9 (0.8) 3.3 (0.9) o0.001
UAE (mg/24 h)a 384 (4.8) 11.7 (2.9) 6 (2.3) o0.001
Plasma creatinine (mmol/l) 299.5 (141.8) 75.5 (15.7) 72.3 (20.5) o0.001
GFR (ml/min/1.72 m2) 22.6 (11.5) 83.8 (16.1) 92.6 (21.2) o0.001
Drug treatment
Insulin therapy alone 77% 3.1% NA —
Insulin and oral drugs 0% 12.5% NA —
Oral drugs only 23% 84.4% NA —
BP-lowering drugs 96% 53.1% NA —
Brachial artery diameter (mm) 4.85 (0.68) 4.15 (0.62) 4.06 (0.74) o0.001
HbA1c, Glycated haemoglobin; FPG, Fasting plasma glucose; BP, blood pressure; TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-
density lipoprotein cholesterol; UAE, urinary albumin excretion; GFR, glomerular filtration rate (estimated by Modification of Diet in Renal Disease Study formula).
Mean (s.d.).
aExpress as geometric mean (antilog s.d.). DMN, diabetic patients with nephropathy; ANOVA, analysis of variance; M, male; F, female.
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administration. Our findings suggest that the major
functional abnormality of diabetic vasculature, upon
development of overt nephropathy, include decreased
flow-induced endothelial NO production and reduced VSMC
responsiveness to NO. In our study, diabetic patients with
overt nephropathy also had greater increase in carotid
IMT than diabetic patients without nephropathy and control
subjects. Taken together, reduced NO production, dysfunc-
tion of VSMC, and increased IMT may contribute to the
markedly escalated cardiovascular risk in patients with
diabetic kidney disease.
Functional defects of diabetic vasculature in nephropathy
In the functional assessment of brachial artery using high-
resolution ultrasound, FMD induced by reactive hyperemia
has been known to be endothelium-dependent mediated
predominantly by NO production from the endothelium.22
In contrast, the vasodilator response to GTN is an endo-
thelium-independent mechanism which reflects VSMC
response to NO. The interpretation of FMD assumes normal
VSMC response to NO. In our study, FMD and GTN-
induced dilation were reduced to similar extent in diabetic
patients with nephropathy suggesting that reduced NO
production and reduced VSMC responsiveness to NO are
both important in this group of patients. Previous studies
have shown that in patients with type II diabetes, endothelial
function of both forearm resistance vessels and conduit
vessels was impaired whereas VSMC function was unaffected.
These studies, however, were performed mainly in diabetic
patients with normoalbuminuria or microalbuminuria.23,24
In contrast, we have included patients with a wide range
of metabolic control and renal function, thus despite
our relatively small sample size, we were able to show
the differential effects of these parameters on FMD and
GTN-induced dilation.
In our study, after adjustment for baseline vessel diameter,
smoking, plasma glucose, and TC were identified as major
determinants of FMD, whereas GTN-induced dilation
was independently predicted by age and albuminuria. In a
previous case–control study involving diabetic patients with-
out overt nephropathy and non-diabetic subjects, Stehouwer
et al.25 reported that FMD was impaired in patients
with microalbuminuria whereas GTN-induced vasodilation
was unaffected. Although we did not find an independent
correlation between microalbuminuria and FMD, such
relationship might be confounded by effects owing to
smoking, plasma glucose, and TC which were also associated
with albuminuria. On the other hand, despite controlling for
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Figure 1 | Comparisons of vascular structure and function in
control subjects and diabetic patients with and without overt
nephropathy and renal insufficiency (panel 1: FMD of brachial
artery; panel 2: GTN-induced dilation of brachial artery;
panel 3: IMT, all data are shown as mean7s.d.).
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Figure 2 | The association between GTN-induced dilation of
brachial artery and urinary albumin excretion in Chinese patients
with varying degree of albuminuria and glycemia. The regression
line (95% CI) is also shown with a correlation coefficient of 0.398
(Po0.001).
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these conventional risk factors, albuminuria remained an
important determinant for GTN-induced dilation. Since
these changes were predominantly observed in patients with
overt nephropathy and renal impairment, it is plausible that
metabolic changes associated with chronic kidney disease
might contribute to these associations. In this regard,
abnormal bone metabolism, increased oxidative stress, and
inflammation owing to retained urotoxins have all been
suggested to accelerate vascular calcification and cause
vascular stiffness in patients with chronic kidney disease,
which can be further aggravated in the presence of diabetes.15
Carotid IMT in diabetic nephropathy
Increased IMT of the common carotid artery is a well-
recognized surrogate marker of early atherogenic changes of
the vasculature.26 In type II diabetic patients with normo-
albuminuria, carotid IMT has been shown to be increased27,28
compared to non-diabetic subjects. While we did not observe
significant differences in IMT between diabetic patients
without nephropathy and control subjects, patients with
diabetic nephropathy had marked increase in IMT. On
multivariate analysis, smoking, GFR, and age were indepen-
dent determinants of IMT, thus lending support to the
adverse effects of the metabolic milieu of chronic kidney
disease on the progression of atherosclerosis with involve-
ment of both vascular structure and function.
Potential mechanisms for vascular defects in diabetic
nephropathy
The mechanisms underlying VSMC and endothelial dysfunc-
tion in diabetic patients are complex, involving inter-
actions between metabolic, hemodynamic, inflammatory,
and growth factors. Besides, glucose-dependent changes such
as increased formation of advanced glycation endproducts
and activation of protein kinase C can further exacerbate
these vascular changes.29,30 In particular, the increased
formation of glycation endproducts can impair the diffusion
of NO across the basement membrane from the endothelium
to VSMC. Alternatively, glycation endproduct accumulation
may diminish the contractile ability of VSMC resulting in
impaired response to GTN in the human forearm vessels. On
the other hand, abnormal composition of low-density
lipoprotein particles in the presence of hyperglycemia and
hypertriglyceridemia may also contribute to impaired
vascular function.31 In support of these results, both plasma
glucose and TC were found to be independent predictors for
FMD in our study.
Another key mediator of vascular dysfunction in the
presence of nephropathy is the accumulation of endogenous
NO synthase inhibitor, asymmetric dimethylarginine.32 In-
deed, the accumulation of asymmetric dimethylarginine has
been shown to correlate with carotid IMT in patients
with end-stage renal disease.33 Although we had not
measured these potential mediators for vascular dysfunction
in our subjects, our overall results provide a possible
explanation for the increased cardiovascular risk in patients
with renal insufficiency with both structural and functional
components.
Study limitations
The majority of our patients with nephropathy were treated
with insulin (77%), which may have beneficial effects on
NO-mediated vascular function, and thus may attenuate the
difference between DMNþ and DMN patients. Never-
theless, most of the vasodilating actions of insulin occur
in the microcirculation and are unlikely to be a major
confounder34 Although acute hyperglycemia might theoreti-
cally interfere with endogenous NO availability,35,36 the
overall evidence remain inconclusive.37 On the other hand,
the use of euglycemic-insulin clamp may induce problems
such as pain which can interfere with local blood flow and is
not always used in vascular studies of diabetic patients.16,23,38
Indeed, in our study, we observed only minor differences in
FMD, GTN-induced dilation, and IMT between the non-DM
and DMN subjects which might be in part due to their near
optimal metabolic control and preserved renal function in
contrast to patients with overt nephropathy. Since our
study did not include patients with significant proteinuria
(UAE4300 mg/day) but preserved GFR, our results may not
be applicable to this group of type II diabetic patients.
In conclusion, vascular defect in type II diabetic patients
with overt nephropathy and renal insufficiency extends
beyond the vascular endothelium and affects VSMC response
to NO. Carotid IMT is also greatly increased in patients with
diabetic nephropathy compared with those without. These
functional and structural abnormalities may contribute to
the markedly escalated cardiovascular risk in patients with
diabetic renal disease.
MATERIALS AND METHODS
Patients and methods
The study was approved by the Chinese University of Hong Kong
Clinical Research Ethics Committee. Twenty-six type II diabetic
subjects with overt nephropathy and moderate renal insufficiency
(DMNþ ) defined as 24 h UAE X300 mg/day on at least two
occasions 6 weeks apart and plasma creatinine 130–260mmol/l
(patients with UAEX300 mg/day but plasma creatinineo130 mmol/
l were excluded) as well as 32 type II diabetic patients without
nephropathy (non-DMN) defined as UAEo300 mg/day on two
occasions and plasma creatinine o80 mmol/l in women and
o106mmol/l in men were recruited from the Diabetes Centre of
the Prince of Wales Hospital. A total of 52 age-matched volunteers
(non-DM) who had no known medical history and fasting plasma
glucose (o5 mmol/l) were selected as control subjects. Type II
diabetes was defined by the 1998 WHO criteria39 and patients with
acute and unprovoked ketotic presentation or who required insulin
within 1 year of diagnosis were excluded.
All subjects arrived at the clinic after at least 10 h overnight
fast without taking any medication on the study day. Informed
written consent was obtained after the subjects were given detailed
explanation about the study. Body weight and height were measured
with subject wearing light clothing and without shoes. Waist
circumference was taken as the mean of two readings of the
minimum circumference between the umbilicus and xiphoid
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process. Hip circumference was taken as the mean of two measure-
ments of the maximum circumference around the buttock and the
symphysis pubis. Supine blood pressure was taken using standard
sphygmomanometer after at least 10 min rest. Korotkoff sound V
was taken as the diastolic blood pressure. Fasting blood samples
were taken for the measurement of fasting plasma glucose, glycated
haemoglobin, plasma creatinine, and full lipid profiles including TC,
high-density lipoprotein cholesterol, triglyceride, and calculated
low-density lipoprotein cholesterol. Twenty-four urine collections
were made to document 24-h UAE after exclusion of urinary tract
infection in all subjects.
Assessment of IMT and endothelial function
All studies were performed in the morning. Subjects lay at rest for at
least 10 min before the first scan. Artery scan of the longitudinal
section of both common carotid arteries from the carotid bulb to
at least 2 cm proximal to the carotid bulb were obtained using a
7-MHz array transducer interfaced to a standard ATL HDI 5000
system with artery intima clearly identified on the ultrasound image.
IMT of the common carotid artery was measured at three random
spots between 1 and 2 cm proximal to the carotid bulb on both
sides. The mean of the six readings were taken. The intraobserver
and interobserver variability were both 1.3%.
The brachial artery was located several centimetres above the
elbow. Arterial scans were then obtained in longitudinal section
using the same ultrasound machine. When a satisfactory transducer
position was located, the skin was marked accordingly and the arm
remained in the same position throughout the study. A resting scan
was recorded for measurement of vessel diameter, and blood flow
velocity was measured by the Doppler flow signal (velocity–time
integral). Reactive hyperemia was produced by inflation of a
pneumatic tourniquet placed on the forearm to 300 mm Hg for
5 min followed by rapid release. A second scan was obtained for
measurement of FMD, starting 30 s before and until 5 min after
deflation. Flow velocity during hyperemia was measured by Doppler
velocimetry immediately following cuff deflation. The subjects
rested for 10–15 min before another scan was obtained, which was
followed by the administration of sublingual GTN, 400 mg and
performance of a final scan 4 min later. All scans were recorded on
supera-VHS videotape for later off-line analysis. The intraobserver
and interobserver variability were 2 and 3.1%, respectively. The
operator was blinded to the identity of the subject but not blinded
to the timing of the examination.
Laboratory assay
Plasma glucose, TC, triglyceride, high-density lipoprotein cholester-
ol, and urinary creatinine:albumin concentrations were measured
on a Hitachi 911 automated analyzer (Boehringer Mannheim,
Mannheim, Germany). Low-density lipoprotein cholesterol was
calculated by the Friedewald’s equation.40 Plasma creatinine
concentration was measured on a Dimension AR system (Dade
Behring, Deerfield, IL, USA). Glycated hemoglobin was measured by
an automated ion-exchange chromatographic method (Bio-Rad
Laboratory, Hercules, CA. Normal range 5.1–6.4%).
Data analysis
In all subjects, IMT was measured as described in the Materials and
Methods section. The diameter of the brachial artery was measured
twice by the same observer who did not know the clinical profiles of
the subjects and the mean of the two readings were taken. The
diameter of the artery during post-deflation period was measured
every 30 s before and until 5 min after deflation to identify the
diameter at maximal dilation for each subject. FMD and GTN-
induced dilation, both expressed as percent changes in vessel
diameter, were calculated from the observer’s measurement using
the average results of four cardiac cycles per condition.
Statistical methods
Statistical analysis was performed using the Statistical Package for
Social Sciences (SPSS 9.0) software. Results are expressed as
mean7s.d. Baseline characteristics of the diabetic patients and
control subjects were compared using analysis of variance, as were
FMD, GTN-induced dilation, and IMT of the three groups. The
Modification of Diet in Renal Disease Study equation was used to
estimate the GFR of all subjects.41 Multiple regression analysis was
used to evaluate correlations between IMT, endothelial function,
clinical, metabolic, and renal parameters. As FMD- and GTN-
induced dilation can be significantly affected by baseline brachial
artery diameter, further analysis was performed using post-FMD
and GTN-induced vascular dilation as independent variables with
adjustment for baseline brachial artery diameter. FMD was the
primary variable for analysis. All other P-values were adjusted for
multiple comparisons. A two-tailed P-value of o0.05 was
considered statistically significant.
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